Canntab Therapeutics Limited (CSE:PILL) (“Canntab” or the “Company”) is pleased to announce the Health Canada approval and launch of the first of its ‘420 Therapeutics’ brand of Cannabis wellness products: Hemp Oil Gel Capsules. Made from purified organic hemp seed oil, the Hemp Oil Gel Capsules are an easy and convenient way to enjoy the health benefits of hemp oil.

Each Hemp Oil Gel Capsule contains 50 milligrams of purified hemp seed oil extracted from cannabis sativa and suspended in high grade coconut oil. These ingredients have been linked to the following health benefits:

  • Omega 3 Fatty Acids (alpha linolenic acid) and Omega 6 Fatty Acids (linolenic acid) are antioxidants that help protect the body’s cells and shields it from the oxidative damage caused by free radicals.
  • Coconut oil contains Lauric acid that is proven to be effective at killing bacteria, fungi and certain viruses.
  • Capric acid and medium triglycerides help increase the body’s energy expenditure for weight control and also aid in building muscle.

Figure 1: Hemp Oil Capsules

Cannot view this image of the Hemp Oil Capsules?
Please visit [] to view this image

Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, “We are excited to announce the launch of Hemp Oil Gel Capsules, which are the first in our innovative line of 420 Therapeutics products. We intend to release additional exciting formulations that combine natural, hemp-based cannabidiol with a range of healthy ingredients. This is only the first step in realizing Canntab’s goal of becoming a leading provider of cannabis oral dosage formulations.”

Mr. Richard Goldstein, Chief Financial Officer of Canntab, added, “All of our 420 Therapeutics products will use state of the art tamper-proof blister packaging, which allows us to avoid the leakage that often occurs when capsules are kept in large bottles, since the capsules kept in bottles frequently bounce off one another and become damaged. Our packaging keeps the underlying product intact, and provides for discretionary and safe consumption of one capsule at a time.”

About 420 Therapeutics

420 Therapeutics Inc. (“420 Therapeutics”) is a wholly-owned subsidiary of Canntab that was created to answer a growing desire for adult use cannabis products that are of high quality, but without the negative effects associated with smoking marijuana. Our research and development protocols ensure that each 420 Therapeutics product offers a uniform dosage of high quality cannabis extract, which we verify through extensive testing. “420 Therapeutics” is also a trademark of Canntab.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!


Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

The information and statements in this news release contain certain forward-looking information relating to the implementation, timing, and roll out of the future 420 Therapeutics products, including ingredients, cannabidiol content, and possible health benefits. This news release also contains certain forward-looking statements relating to future business objectives. This forward-looking information is subject to certain risks and uncertainties and may be based on assumptions that could cause actual results to differ materially from those anticipated or implied in the forward-looking information. Canntab’s forward-looking information is expressly qualified in its entirety by this cautionary statement. Except as required by law, Canntab undertakes no obligation to publicly update or revise any forward-looking information.

Click here to connect with Canntab Therapeutics Limited (CSE:PILL) for an Investor Presentation.


TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced Jason Ackerman Chief Executive Officer and Executive Chairman of TerrAscend, Keith Stauffer Chief Financial Officer, and Jason Wild Chairman, will participate in three upcoming conferences:

  • Cowen’s 3rd Annual Boston Cannabis Conference, a virtual event taking place November 30-December 2 , 2020. Jason Ackerman will participate in a panel, U.S. MSOs: The West, on November 30, 2020 at 10:25 a.m. ET . Management will also host one-on-one meetings with investors throughout the conference.
  • 2020 Cantor Fitzgerald Virtual Cannabis MSO Summit, a virtual event taking place on December 15-16, 2020 . Jason Ackerman is scheduled to participate in a fireside chat on December 16 th at 1:00 p.m. ET . To register for the fireside chat: Click Here
  • 23 rd Annual Needham Virtual Growth Conference, a virtual event taking place January 11-15, 2021 . Jason Ackerman is scheduled to participate in a fireside chat on January 14, 2021 at 2:45 p.m. ET . Management will also host one-on-one meetings with investors throughout the conference. To register for the fireside chat: Click Here

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Keep reading... Show less
  • Aurora strategically positioned within two of the largest legal cannabis markets outside of Canada
  • Agreement with Israeli leader Cantek provides access to Israel’s drugstore channel
  • Finished product is co-branded under Aurora and Cantek brands


Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today it has entered into a strategic Supply Agreement (the “Agreement”) with Cantek Holdings (“Cantek”), one of Israel’s leaders in the medical cannabis field.

Keep reading... Show less


Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, is exploring a potential coin offering, following the results of its first Testnet where the Arcology team achieved major product development milestones

Keep reading... Show less

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased Aurora Cannabis, Inc. (NYSE: ACB) securities between February 13, 2020 and September 4, 2020 (the “Class Period”). Investors have until December 1, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

Keep reading... Show less

The coming together of two Canadian beverage industry leaders will form a unique vertical in the plant-based mineral and cannabis beverage sectors

Not for Distribution to U.S. Newswire Services or for Dissemination in the United States

Keep reading... Show less